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Meena Kumari,3 Leonard C. Schalkwyk,2 and Jonathan Mill1,*
Characterizing the complex relationship between genetic, epigenetic, and transcriptomic variation has the potential to increase under-
standing about the mechanisms underpinning health and disease phenotypes. We undertook a comprehensive analysis of common
genetic variation on DNA methylation (DNAm) by using the Illumina EPIC array to profile samples from the UK Household Longitudi-
nal study. We identified 12,689,548 significant DNA methylation quantitative trait loci (mQTL) associations (p < 6.52 3 1014) occur-
ring between 2,907,234 genetic variants and 93,268 DNAm sites, including a large number not identified by previous DNAm-profiling
methods. We demonstrate the utility of these data for interpreting the functional consequences of common genetic variation associated
with > 60 human traits by using summary-data-based Mendelian randomization (SMR) to identify 1,662 pleiotropic associations be-
tween 36 complex traits and 1,246 DNAm sites. We also use SMR to characterize the relationship between DNAm and gene expression
and thereby identify 6,798 pleiotropic associations between 5,420 DNAm sites and the transcription of 1,702 genes. OurmQTL database
and SMR results are available via a searchable online database as a resource to the research community.Introduction
DNA methylation (DNAm), an epigenetic modification
to cytosine, is involved in mediating the developmental
regulation of gene expression and function, as well as
transcriptional processes such as genomic imprinting and
X chromosome inactivation.1,2 Although often regarded
as a mechanism of transcriptional repression, the relation-
ship between DNAm and gene expression is highly com-
plex and not fully understood.3 Gene-body DNAm, for
example, is often associated with active expression4 and
also influences other transcriptional processes, including
alternative splicing and promoter usage.5 This dynamic
property of DNAm means it can vary across samples and
might underlie phenotypic differences. There is growing
interest in characterizing the variation of DNAm across
populations6,7 and in the role of DNAm in disease, and
recent epigenome-wide association studies (EWASs) have
identified robust associations between variable DNAm
and cancer,8 as well as a diverse range of other complex
phenotypes, including rheumatoid arthritis [MIM:
180300],9 body-mass index,10 schizophrenia [MIM:
181500],11 and Alzheimer disease [MIM: 104300].12 Char-
acterizing the complex relationship between genetic,
epigenetic, and transcriptomic variation will increase un-
derstanding about the mechanisms underpinning health
and disease phenotypes. Twin and family studies have
demonstrated that population-level variation in DNAm is
under considerable genetic control, although these effects
vary across genomic loci, developmental stages, and
different cell and tissue types.13–17 Studies in a variety of
tissues, including brain, whole blood, pancreatic islet cells,1University of Exeter Medical School, University of Exeter, Exeter EX2 5DW, Un
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tions between common DNA sequence variants and
DNAm.17–22 These DNAm quantitative trait loci (mQTLs)
are primarily cis-acting, are enriched in regulatory chro-
matin domains and transcription-factor binding sites,
and have been shown to colocalize with gene expression
quantitative trait loci (eQTLs).3,17,23
There is considerable interest in using mQTLs, along
with other types of molecular QTLs, to interpret the func-
tional consequences of common genetic variation associ-
ated with human traits, especially because the actual
gene(s) involved in mediating phenotypic variation are
not necessarily the most proximal to the lead SNPs identi-
fied in genome-wide association studies (GWASs). Of note,
GWAS variants are enriched in enhancers and regions of
open chromatin,24,25 reinforcing the hypothesis that
most common genetic risk factors influence gene regula-
tion rather than directly affecting the coding sequences
of transcribed proteins.26 Importantly, evidence for the
co-localization of genetic variants associated with both
phenotypic and regulatory variation is not sufficient to
show that the overlapping association signals are causally
related; additional analytical steps are needed to distin-
guish pleiotropic effects—i.e., where the same variant is
influencing both outcomes, although not necessarily
dependently—from those that are an artifact of linkage
disequilibrium (LD). We recently extended the use of
one approach—summary-data-based Mendelian randomi-
zation (SMR), which was initially used in conjunction
with expression quantitative trait loci (eQTL) data27—to
prioritize genes for GWAS-nominated loci using mQTL
data.28ited Kingdom; 2School of Biological Sciences, University of Essex, Colches-
University of Essex, Colchester CO3 3LG, United Kingdom
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Building on our previous work, we used the Illumina
EPIC array and imputed SNP data to identify mQTLs asso-
ciated with variable DNAm at 850,000 sites across the
genome in samples from the Understanding Society UK
Household Longitudinal Study (UKHLS) (n ¼ 1,111). We
then used these mQTLs within the SMR framework to
refine genetic association data from publicly available
GWAS datasets in order to prioritize genes involved in
63 complex traits and diseases. We subsequently used the
SMR approach to identify pleiotropic relationships be-
tween DNAm and variable gene expression by using pub-
licly available whole-blood gene eQTL data. Our mQTL
database and SMR results are available via a searchable on-
line database as a resource to the research community (see
Web Resources).Subjects and Methods
Sample Description
The British Household Panel Survey (BHPS) began in 1991, and in
2010 it was incorporated into the larger UKHLS29 (also known as
Understanding Society), which is a longitudinal panel survey of
40,000 UK households from England, Scotland,Wales, and North-
ern Ireland. Since 1991, annual interviews have collected sociode-
mographic information, and in 2011–2012, biomedical measures
and blood samples for BHPS participants were collected during a
nurse visit in the participant’s home. Respondents were eligible
to give a blood sample if they had taken part in the previous
main interview in English; were 16 or older; lived in England,
Wales, or Scotland; were not pregnant; and met other conditions
detailed in the user guide.30 For each participant, non-fasting
blood samples were collected through venipuncture; these were
subsequently centrifuged so that plasma and serum were sepa-
rated, and samples were aliquoted and frozen at 80C. DNA
has been extracted and stored for genetic and epigenetic analyses.Genome-wide Quantification of DNAm
DNAm was profiled in DNA extracted from whole blood for 1,193
individuals who were aged from 28 to 98; who were eligible for
and consented to both blood sampling and genetic analysis;
who had been present at all annual interviews between 1999
and 2011; and whose time between blood sample collection and
processing did not exceed 3 days. Eligibility requirements for
genetic analyses meant that the epigenetic sample was restricted
to participants of white ethnicity. The EZ-96 DNA Methylation-
Gold kit (Zymo Research) was used for treating 500 ng of DNA
from each sample with sodium bisulfite. DNAm was quantified
with the Illumina Infinium HumanMethylationEPIC BeadChip
run on an Illumina iScan System according to the manufacturer’s
standard protocol. Samples were randomly assigned to chips and
plates so that batch effects would be minimized. In addition, the
inclusion of a fully methylated control (CpG Methylated HeLa
Genomic DNA; New England BioLabs) in a random position on
each plate facilitated sample tracking and helped to resolve exper-
imental inconsistencies and confirm data quality.DNAm Data Preprocessing
Raw signal intensities were imported from.idat files into the R sta-
tistical environment31 and converted into beta values (the propor-The Americantion of DNA methylation at individual sites was measured) with
the bigmelon package.32 These data were processed via a standard
pipeline including the following steps: (1) detection of outlier
samples via principal-component analysis and Mahalanobis dis-
tance equivalents, (2) confirmation of complete bisulphite conver-
sion via control probes, (3) comparison of estimated age from the
data via the Horvath Epigenetic Clock algorithm33 and reported
age at sampling, and (4) visualization of principal components.
Data were normalized with the dasen function within the
wateRmelon package,34 which performs background adjustment
and between-sample quantile normalization of methylated (M)
and unmethylated (U) intensities separately for type I and
type II probes. Samples that were dramatically altered as a result
of normalization were excluded on the basis of the difference
between the normalized and raw data; those with a root mean
square and standard deviation > 0.05 were removed. Samples
were then filtered so that those with >1% of sites with a detection
p value> 0.05 were excluded. Finally, DNA-methylation sites with
a bead count <3 were excluded along with those in which >1%
of the sample had a detection p value > 0.05. The raw DNA
methylation data from the final sample set was then re-nor-
malzsed with the dasen function. The final dataset included
857,071 DNA-methylation sites and 1,175 individuals for subse-
quent analysis. These DNAm data are available upon request
through the EuropeanGenome-Phenome Archive under accession
code EGAS00001001232.Annotation of DNAm Sites
The genomic location of DNAm sites along with genic, DNase
hypersensitivy sites and open chromatin annotation were taken
from the manifest files provided by Illumina and downloaded
from the product support pages (see Web Resources).Genotyping and Imputation
UKHLS samples were genotyped with the Illumina Infinium
HumanCoreExome BeadChip Kit as previously described
(12v1-0).35 This array contains a set of >250,000 highly informa-
tive genome-wide tagging single-nucleotide polymorphisms
(SNPs) as well as a panel of functional (protein-altering) exonic
markers, including a large proportion of low-frequency (MAF
1%–5%) and rare (MAF < 1%) variants. Genotype calling was per-
formed with the gencall algorithm within GenomeStudio (Illu-
mina). After only the samples with matched DNAm data were
selected, variants were refiltered prior to imputation. PLINK36
was used for removing samples with >5% missing data. We also
excluded SNPs characterized by >5% missing values, a Hardy-
Weinberg equilibrium p value < 0.001, and a minor-allele fre-
quency of <5%. For identification of related samples, SNPs under-
went LD pruning, and the –genome command in PLINK was used
for calculating the proportion of identity-by-descent for all pairs
of samples; 58 pairs of related samples (PI_HAT > 0.2) were iden-
tified, and randomly excluding one individual from each pair
ensured that the samples were independent. These data were
then imputed with the 1000 Genomes phase 3 version5 reference
panels SHAPEIT and minimac3.37 Best-guess genotypes were
called, and variants were filtered to those with a minor-allele fre-
quency >0.01 and an INFO score >0.8. Because variants were
named using their locations (‘‘chr:pos’’) and variant type (SNP/
INDEL), duplicate variants were also excluded. Principal compo-
nents were calculated from the imputed genotype data via GCTA
(a tool for genome-wide complex-trait analysis).38 16 samplesJournal of Human Genetics 103, 654–665, November 1, 2018 655
were identified as being outliers (defined as more than 2 standard
deviations from themean) in a scatterplot of the first two principal
components andwere excluded from subsequent genetic analyses.
Principal components were then recalculated for inclusion as
covariates in QTL analyses. The imputed genetic variants were
then filtered so that variants characterized by>5%missing values,
a Hardy-Weinberg equilibrium p value <0.001, a minor-allele
frequency of <5%, and a minimum of five observations in each
genotype group were excluded. These genotype data are available
on application through the European Genome-phenome Archive
under accession code EGAS00001001232.DNAm Quantitative-Trait Loci
Cross-hybridizing probes, probes with a common SNP (European
population minor-allele frequency > 0.01) within 10 bp of the
CpG site or a single base extension39,40 and probes on the sex
chromosomes were excluded from the QTL analysis. In addition,
977 substandard probes identified by Illumina were also excluded.
We performed a genome-wide mQTL analysis; in total, we tested
766,714 DNAm sites against 5,210,475 genetic variants by using
the R package MatrixEQTL.41 This package enables fast computa-
tion of QTLs by only saving those more significant than a pre-
defined threshold (set to p ¼ 1 3 108 for this analysis). We fitted
an additive linear model to test whether the number of alleles
(coded 0,1,2) predicted DNAm at each site; we included covariates
for age, sex, six estimated cellular composition variables (B cells,
CD8 T cells, CD4 T cells, monocytes, granulocytes, natural killer
T cells),42,43 two binary batch variables, and the first ten principal
components from the genotype data to control for ethnicity
differences. We used a Bonferroni-corrected multiple-testing
threshold, set to genome-wide significance for GWAS and divided
by the number of DNAm sites tested (i.e., 5 3 108/766714 ¼
6.523 1014). We used the clump command in PLINK36 to identify
the number of independent associations for each DNAm site
with more than 1 significant mQT by using the following param-
eters: –clump-p1 1e-8–clump-p2 1e-8–clump-r2 0.1–clump-kb 250.Bayesian Co-localization
Out of all DNAm sites with at least 1 significant mQTL (p < 1 3
1010), all pairs of DNAm sites located on the same chromosome
and within 250 kb of each other were tested for co-localization.
Because data for all SNPs (regardless of significance) are required
for this analysis, first, the mQTL analysis was rerun for these
DNAm sites so that all association statistics (p value, regression
coefficient, and t-statistic, so that the standard error could be in-
ferred) could be recorded for all SNPs within 500 kb of the
DNAm site. Co-localization analysis was performed as previously
described44 with the R coloc package (see Web Resources). From
our mQTL results we input the regression coefficients, their vari-
ances, and SNP minor-allele frequencies, and we left the prior
probabilities as their default values. This methodology allowed
us to quantify the support across the results of each GWAS for
five hypotheses by calculating the posterior probabilities, denoted
as PPi for hypothesis Hi.
H0: there exist no causal variants for either CpG site;
H1: there exists a causal variant for CpG1 only;
H2: there exists a causal variant for CpG2 only;
H3: there exist two distinct causal variants, one for each
CpG; or
H4: there exists a single causal variant common to both CpGs.656 The American Journal of Human Genetics 103, 654–665, NovemSummarized Mendelian Randomization Analysis 1:
Identifying Putative Pleiotropic Relationships between
DNAm and Complex Traits
SMR analysis between DNAm and complex traits was performed
with publicly available software (see Web Resources) as previously
described.27,28 Publicly available genome-wide association study
(GWAS) results were downloaded from a range of sources and con-
verted to the appropriate format for the SMR analysis.We renamed
SNPs in the 1000 Genomes format (chr:bp) to align them with the
mQTLoutput by using dbSNPversion 141 (where SNP locations for
hg19 were not provided in the results file). Where allele frequency
was not provided, it was taken from the European subset of 1000
Genomes (phase 3, version 5). Details for how each set of results
was processed can be found in Table S4.We used significantmQTLs
(p< 13 1010) calculated in the UKHLS sample to identify genetic
instruments for 126,457DNAmsites thatwere included in the SMR
analysis. The SMR test comprises of two steps. First, we performed a
two-sample Mendelian randomization with the two-step least-
squares (2SLS) approach by using the effect size of the top cis-
QTL SNP and its corresponding effect in the GWAS. The signifi-
cance threshold for this part of test was set at 3.95 3 107, calcu-
lated by the Bonferroni correction method and adjusted for the
number of DNAm sites tested (0.05/126,457). Second, we tested
for heterogeneity of effects by using alternative SNPs as the instru-
mental variable, on the basis of the theory that if both DNAm and
the GWAS trait were associated with the same causal variant, the
choice of SNP would be irrelevant, whereas if they were associated
with different causal variants, the differing linkage disequilibrium
relationships between the instruments and each causal variant
would lead to variation in the estimated effect between the trait
and DNAm. Non-significant heterogeneity (heterogeneity in
dependent instruments [HEIDI] p > 0.05) indicates that there is a
pleiotropic effect on a GWAS trait and DNAm. This approach was
repeated with publicly available eQTL data from Westra et al.;45
in this analysis, significant pleotropic associations between gene
expression and complex traits were selected as those with SMR p
< 8.38 3 106 (corrected for 5,966 gene expression probes tested)
and HEIDI p > 0.05.Summarized Mendelian Randomization Analysis 2:
Identifying Putative Pleiotropic Relationships between
DNAm and Gene Expression
We used a second application of the SMR analysis to identify pleio-
tropic relationships between DNAm and gene expression. Gene
eQTL results from the Westra eQTL study45 were downloaded
along with the SMR software. SNP IDs were converted to the
1000 Genomes format (so they would match the mQTL output),
and SNP frequencies were taken from the European subset of
1000 Genomes (phase 3, version 5). These data included eQTLs
at 5,966 probes. All pairs of CpG and genes where tested as long
as (1) the CpG had a significant mQTL (p < 1 3 1010), (2) the
gene had a significant eQTL (p < 5 3 108), and (3) there was a
common genetic variant tested within 500 kilobases of the gene
expression probe and DNAm site. In total, 488,342 pairs of
DNAm sites and gene expression transcripts were tested; therefore,
the significance threshold for the first stage of the SMR test was set
to p < 1.02 3 107 after a Bonferroni correction for the number
of tests was applied. Consistent with all other SMR analyses in
this manuscript, a non-significant heterogeneity test (HEIDI
p > 0.05) in step 2 of the SMR analysis was used for classifying
pleiotropic relationships from artifacts of linkage disequilibrium.ber 1, 2018
Figure 1. DNA-Methylation Quantitative-
Trait Loci Are Predominantly cis-Acting
and Enriched in Sites at Which DNAm Is
Highly Heritable
(A) The genomic distribution of Bonferroni-
significant (p ¼ 6.52 3 1014) mQTLs in
whole blood; the position on the x axis indi-
cates the location of Illumina EPIC array
probes, and the position on the y axis indi-
cates the location of genetic variants.
The color of the point corresponds to the
difference in DNA methylation per allele
compared to the reference allele; the largest
effects are plotted in dark red. A clear posi-
tive diagonal can be observed, demon-
strating that the majority of mQTLs are
associated with genotype in cis.
(B) A bar plot of the percentage of DNA-
methylation sites associated with common
genetic variation and grouped by previous
reported estimates of heritability (percent
variation in DNAm is explained by additive genetic factors taken from van Dongen et al.13). Each bar plot demonstrates the percentage
of DNA-methylation sites with Bonferroni significant genetic effects in cis only (blue), trans only (green), and both cis and trans (red) and
with no significant genetic effects (white).Enrichment Analyses
DNAm sites were annotated to genes and CpG islands with the in-
formation provided in the Illumina manifest file, which is based
on the UCSC RefGene and CpG island databases. Sites are anno-
tated to genes if they are located within the gene body or up to
1,500 base pairs form the transcription start site. Sites are anno-
tated to CpG islands if they are located within the boundaries of
a CpG island, to a shore if they are located up to 2,000 base pairs
from an island, or to a shelf if they are between 2,000 and 4,000
base pairs from an island. Frequency tables were used for recording
the number of sites annotated to each feature category, and Chi-
square tests were used for identifying different distributions across
these annotation categories between all tested DNAm sites and the
subset of sites considered for enrichment analysis (e.g., all DNAm
sites with at least one significant mQTL).
Data Availability
Summary statistics for all Bonferroni-significant DNA-methyl-
ation quantitative-trait loci are available for download from the
Complex Disease Epigenomics Group website, where readers can
also explore many of the results included in this manuscript
through our interactive web application. Analysis scripts used in
this manuscript are available on GitHub, and data on phenotypes
linked to DNA methylation are available on METADAC. See the
Web Resources and the Accession Numbers sections.Results
Additional mQTL Associations Identified with the
Illumina EPIC Array
An overview of our study design is presented in Figure S1.
We tested 5,210,475 imputed genetic variants against the
766,714 DNAm sites that were on the Illumina EPIC array
and that passed our stringent QC criteria (see Subjects and
Methods).We identified 12,689,548 significantmQTL asso-
ciations (we used a conservative Bonferroni-corrected
threshold of p < 6.52 3 1014) between 2,907,234 genetic
variants and 93,268 DNAm sites (Table S1; Figure 1A); thereThe Americanwas a mean percentage point change in DNAm per addi-
tional reference allele of 3.46% (SD ¼ 3.01%) across all
mQTL-associated sites. Existing mQTL databases have
been almost exclusively generated with the Illumina 450K
array; more than half of the DNAm sites (n ¼ 48,099,
51.6%; Table S2) that we identify as being associated with
genetic variationwith the Illumina EPIC array involve addi-
tional content not previously interrogated (Figure S2).
Importantly, these additional mQTL associations are anno-
tated to 5,172 genes not included inmQTLdatabases gener-
ated with the Illumina 450K array (Figure S3). DNAm sites
associated with genetic variation are associated with a me-
dian of 65 (interquartile range¼ 22–162) mQTLs, probably
reflecting linkage disequilibrium (LD) relationships be-
tween proximal variants. In contrast, each mQTL variant
is associated with a median of two (interquartile range ¼
1–5) DNAm sites, and the majority of mQTL SNPs
(n ¼ 1,003,238, 34.5%) are associated with DNAm at only
a single site (Figure S4). We performed LD clumping of the
results for each DNAm site to identify the number of
independent associations for each DNAm site (see Subjects
and Methods); this process reduced the number of mQTL
associations (p< 6.523 1014) to 161,761 (1.27%of the to-
tal number of unclumped significantmQTL associations); a
median of 1 (interquartile range¼ 1–2) mQTL variant asso-
ciated with each DNAm site (Figure S5). At a more relaxed
‘‘discovery’’ threshold (p < 13 1010), we identified a total
of 17,051,673 mQTL associations between 3,281,391 ge-
netic variants and 114,595 DNAm sites; these results are
available in a searchable database (see Web Resources).mQTL Associations Predominantly Occur in cis and
Influence DNAm at Sites Known to Be Influenced by
Heritable Factors
Consistent with the results of previous studies, we found
that the majority of mQTL associations (n ¼ 11,679,376;Journal of Human Genetics 103, 654–665, November 1, 2018 657
92%) occur in cis, defined as situations where the distance
between mQTL SNP and DNAm site is %500 kb17,18,20,22
(Figure 1A). Cis mQTL variants are typically associated
with larger effects on DNAm than those acting in trans
(average cis effect ¼ 3.48% change in DNAm per allele,
average trans effect ¼ 3.26% change in DNAm per allele;
Mann-Whitney p < 2.23 3 10308) (Figure S6). Further-
more, among cis mQTL associations, both significance
and effect size increase as the distance between the genetic
variant and DNAm site decreases (Figure S7). Compared to
other tested DNAm sites, those associated with at least one
mQTL variant (after correction for the number of tests per-
formed [see Subjects and Methods], p < 6.52 3 1014) are
significantly enriched in intergenic regions and less likely
to be located within both gene bodies (Chi square test:
p < 2.23 3 10308; Figure S8; Table S3A) and CpG islands
(Chi square test p < 2.23 3 10308; Figure S9; Table S3B).
We used quantitative genetic data from a study of DNAm
in monozygotic and dizygotic twins13 to show that
DNAm at sites associated with at least one mQTL variant
is more strongly influenced by heritable (additive genetic)
factors than are other tested DNAm sites (mQTL sites:
median heritability, h2, ¼ 55% [interquartile range ¼
38%–71%]; all DNAm sites: median h2 ¼ 12% [interquar-
tile range ¼ 5%–31%]; Mann-Whitney p < 2.23 3 10308;
Figure S10). Overall, the proportion of sites at which
DNAm is associated with an mQTL variant increases as a
function of the estimated additive genetic influence
derived from twin analyses (Figure 1B). Interestingly, there
is no significant difference in the contribution of additive
genetic effects to variance in DNAm at sites associated
with cis (median h2 ¼ 56%; interquartile range ¼ 39%–
72%) and trans (median h2 ¼ 57%; interquartile range ¼
32%–76%) mQTL variants (Mann-Whitney p ¼ 0.910).
Proximal DNA-Methylation Sites Share Genetic
Associations
Similar to the LD relationships that exist between prox-
imal genetic variants, DNAm levels are often correlated
between proximally located DNAm sites.14,46 To further
characterize the genetic architecture of DNA methylation,
we investigated whether shared genetic effects on multiple
DNAm sites underlies this regional correlation structure.
Although genetic variants are often associated with varia-
tion at multiple DNAm sites (Figure S4), this does not
establish a shared genetic effect; shared genetic signals
influencing a pair of DNAm sites might result from two
distinct causal genetic variants that are in strong LD. To
formally test whether neighboring DNAm sites are influ-
enced by the same causal variant, we used a Bayesian co-
localization approach44 to interrogate all pairs of DNAm
sites characterized as being located within 250 kb of each
other and associated with at least one significant mQTL
variant at our ‘‘discovery’’ significance threshold (p < 1 3
1010). Our analyses assessed 3,535,812 pairs of DNAm
sites with a median distance between DNAm sites of
110,493 bp (interquartile range ¼ 47,914–178,085) and658 The American Journal of Human Genetics 103, 654–665, Novemcompared the pattern of mQTL associations for both
DNAm sites to test whether they index an association
with either the same causal variant or two distinct causal
variants. We found that the posterior probabilities for
virtually all of these (n ¼ 3,520,781 [99.6%], median dis-
tance of 110,319 bp [interquartile range ¼ 47,803–
177,948]) supported a co-localized association within the
same genomic region (PP3 þ PP4 > 0.99). Of these,
281,898 pairs (8%) had sufficient support for the associa-
tion of both DNAm sites with the same causal mQTL
variant (PP3 þ PP4 > 0.99 and PP4/PP3 > 1; Table S4);
234,460 pairs (6.6%) had ‘‘convincing’’ evidence (PP3 þ
PP4 > 0.99 and PP4/PP3 > 5) for co-localization of the
same mQTL association according to the criteria of Guo
and colleagues.47 DNAm sites that shared genetic effects
with at least one other DNAm site co-localize with a me-
dian of three other DNAm sites, indicating a complex rela-
tionship between genetic variation and DNAm in cis.
Figure 2, for example, demonstrates that chromosome 9
contains a broad genomic region (>400 kb) where 38
DNAm sites—spanning seven genes—have a common un-
derlying genetic signal. Of note, these DNAm sites are not
contiguous; a small number of genetically mediated
DNAm sites located within this region do not share the
same mQTL signal. Pairs of DNAm sites with a shared
causal mQTL variant are enriched for concordant direc-
tions of effect (71.2% pairs with positive correlations
versus 28.8% pairs with negative correlations, binomial
test p ¼ 1.48 3 10323; Figure S11). Furthermore, these
pairs are located relatively close together (median distance
between convincing co-localized pairs ¼ 12,394 bp [inter-
quartile range ¼ 1,004–49,110]), with evidence that the
shared genetic architecture is structured around annotated
genomic features. Co-localized pairs of DNAm sites are
significantly more likely to be annotated to the same
gene (OR ¼ 6.08, Fisher’s test p < 2.23 3 10308) or CpG
island (OR ¼ 1.54, Fisher’s test p < 2.23 3 10308) than
non-co-localized pairs. Where pairs of DNAm sites with a
shared genetic signal are annotated to the same gene,
they are nominally less likely to be annotated to the
same feature than are pairs of DNAm sites annotated to
different genes (OR ¼ 0.956, Fisher’s test p ¼ 2.52 3 107),
suggesting that where genetic variation influences DNAm
at multiple sites across a gene these sites do not necessarily
cluster by genic feature and can be located anywhere from
the transcription start site to the end of the last exon.
DNAm is more likely to be positively correlated between
pairs of co-localized sites annotated to the same gene
than between pairs of sites annotated to different genes
(OR ¼ 1.85, Fisher’s p < 2.23 3 10308), a result driven
predominantly by pairs of DNAm sites annotated to the
same feature within that gene (OR ¼ 1.57, Fisher’s test
p¼ 3.413 10135) rather than those annotated to different
features within a gene. Finally, pairs of DNAm sites with
shared genetic effects annotated to the same genic feature,
although not necessarily the same gene, are more likely to
be positively correlated than pairs annotated to differentber 1, 2018
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Figure 2. Shared Genetic Architecture be-
tween Neighboring DNA-Methylation Sites
Heatmap of Bayesian co-localization results
for all pairs of DNA-methylation sites with
at least one significantmQTL (p< 13 1010)
in a genomic region on chromosome 9
(chr9:124783559–125216341). Columns
and rows represent individual DNA-methyl-
ation sites (ordered by genomic location).
The color of each square indicates the
strength of the evidence for a shared genetic
signal (from yellow [weak] to red [strong]);
this strength is calculated as the ratio of the
posterior probabilities that they share the
same causal variant (PP4) compared to two
distinct causal variants (PP3). The ratio was
bounded to a maximum value of 10; gray in-
dicates pairs of DNA-methylation sites that
were not tested for co-localization.genic features (OR ¼ 1.73, Fisher’s p < 2.23 3 10308;
Figure S12).
DNAm QTL Have Utility for Refining GWAS Signals for
Complex Traits
Genetic variants identified in GWAS analyses rarely index
protein-coding changes. Instead, they are hypothesized
to influence gene regulation because they are enriched
in regulatory motifs, including enhancers and regions of
open chromatin.24,26 There is considerable interest
in using regulatory QTLs to refine genetic association sig-
nals and prioritize potentially causal genes within the
extended genomic regions identified in GWASs.17,27,48,49
We next extended our previous application of the SMR
approach28 to test 126,457 DNAm sites identified at our
‘‘discovery’’ mQTL threshold (p < 1 3 1010) against
63 complex phenotypes with GWAS data (Table S5). TheThe American Journal of Human Genfirst stage of the SMR approach uses
the most significantly associated
mQTL SNP—that has also been tested
in the GWAS dataset—as an instru-
mental variable and implements a
two-step least-squares (2SLS) approach
to compare the estimated associations.
Using this approach, we identified
5,848 associations (p < 3.95 3 107
corrected for 126,457 DNAm sites) be-
tween 40 complex traits and 5,849
unique DNAm sites (Figure S13).
Because the associations identified in
this way potentially reflect two highly
correlated but different causal variants
for the GWAS trait and DNAm, the sec-
ond stage of the SMR method repeats
the analysis with alternative mQTL
SNPs as the instrument. If there is a sin-
gle causal variant associated with both
the phenotype and DNAm, the associ-
ation statistics will be identical regard-less of the selected instrument. In contrast, if there are two
separate causal variants, each correlated with the instru-
ment, there will be variation in the results. To distinguish
between these scenarios, we applied the heterogeneity in
dependent instruments (HEIDI) test to select associations
with non-significant heterogeneity (HEIDI p > 0.05) and
identified a refined set of 1,662 associations between 36
complex traits and 1,246 DNAm sites (Table S6).
Because the power of the SMR approach to detect pleio-
tropic associations reflects, in part, the power of the initial
complex-trait GWAS, it is unsurprising that the highest
number of SMR associations was found for traits character-
ized by the largest number of GWAS signals, such as height
(423 significant GWAS loci, 506 SMR pleiotropic associa-
tions)50 and inflammatory bowel disease [MIM: 266600 ]
(168 significant GWAS variants, 127 SMR pleiotropic asso-
ciations).51 In contrast, no SMR associations were foundetics 103, 654–665, November 1, 2018 659
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Figure 3. Summary-Data-Based Mendelian Randomization
(SMR) Analysis Using Quantitative Trait Loci Associated with
DNA Methylation (mQTL) and Gene Expression (eQTL) Impli-
cates a Role for LIME1 in Crohn Disease
Shown is a genomic region on chromosome 20 (chr20: 62335000–
62371000) identified in a recent Crohn disease GWAS performed
by Liu et al.51 Genes located in this region are shown at the
top, exons are indicated by thicker bars, and the red arrows
indicate the direction of transcription. The scatterplot depicts
the –log10 p value (y axis) against genomic location (x axis)
from the SMR analysis (where circles represent Illumina EPIC array
DNA-methylation sites, squares represent gene expression probes,
and solid green and red highlight those with a non-significant
HEIDI test for DNA methylation and gene expression, respec-
tively). The green and red horizontal lines represent the multi-
ple-testing corrected threshold for the SMR test using mQTL and
eQTL, respectively.for traits with few or no genome-wide-significant SNPs;
such traits included parental age at death (0–1 significant
GWAS variants),52 insulin secretion rate (no significant
GWAS variants),53 and whether a person has ever smoked
(no significant GWAS variants).54 We compared our SMR
results to those obtained with our previous mQTL data-
set—generated from a smaller number of samples—and
observed high rates of replication for loci that were tested
in both analyses. Because our previous SMR analysis was
based on a subset of 43 traits and the reduced content of
the Illumina 450K array, 842 pleiotropic associations re-
ported in the current analysis were taken forward for repli-
cation; DNAm at 519 (33.0%) of these was associated with
an mQTL variant, and therefore these associations had
been tested in our previous SMR study; 268 (51.6%) were
characterized by significant pleiotropic association in
both studies. Furthermore, the vast majority of associa-
tions tested in both datasets (516; 99.4%) were in the
same direction; this was significantly more than would
be expected by chance (sign test p ¼ 2.72 3 10149;
Figure S14), suggesting that there are many additional
true signals in those that did not meet the stringent criteria
for significance used in both studies.
In order to prioritize genes for each complex trait, we
characterized the genic location of associated DNAm sites.
1,269 (76.3%) of the identified pleiotropic associations660 The American Journal of Human Genetics 103, 654–665, Noveminvolve DNAm sites located either within a gene or less
than 1500 bp from the transcription start site; this rate is
significantly higher rate than that for all DNAm sites tested
in our SMR analysis (OR ¼ 1.64, Fisher’s test p ¼ 1.12 3
1018). To further explore these 786 pleiotropic associa-
tions—occurring between 577 genes and 32 complex
traits—we extended our SMR analyses to incorporate a pub-
licly available whole-blood gene eQTL (n ¼ 5,311 individ-
uals) dataset.45 Expression of 232 (40.2%) of our identified
genes was significantly associated with an eQTL variant,
and we used these to test for pleiotropic associations be-
tween gene expression level and the GWAS trait. These an-
alysesprovided additional support for 138of thepleiotropic
associations identified with mQTL data, supporting a
relationship between 33 genes and 17 complex traits
(Table S7). Figure 3, for example, highlights an association
between the regulation and expressionofLIME1 andCrohn
disease [MIM:266600]; this association is supportedbySMR
analyses incorporating both mQTL and eQTL data.
Pleiotropic Associations between DNAm and Gene
Expression
Although it is widely hypothesized that DNAm influences
gene expression, its relationship with transcriptional activ-
ity is not fully understood. DNAm across CpG-rich pro-
moter regions, for example, is often assumed to repress
gene expression via the blockage of transcription-factor
binding and the attraction of methyl-binding proteins.55
DNAm in the gene body, in contrast, is hypothesized to
be a marker of active gene transcription5,56 and to poten-
tially play a role in regulating alternative splicing and iso-
form diversity. To identify associations between DNAm
and gene expression, we applied the SMR approach to
DNAm sites identified as being associated with an mQTL
at our ‘‘discovery’’ significance threshold, located within
a megabase of a gene expression probe included in the
eQTL dataset generated by Westra and colleagues.45 In to-
tal, we tested 488,342 pairs and explored relationships be-
tween 96,694 DNAm sites and 4,721 gene expression
probes annotated to 4,049 genes (Figure S15). On average,
each DNAm site was tested against amedian of four expres-
sion probes (interquartile range ¼ 2–7) mapping to a me-
dian of three genes (interquartile range ¼ 2–6). In contrast,
each expression probe was tested against a median of
85 DNAm sites (interquartile range ¼ 56–130). Of these,
40,404 pairs (8.27%)—comprising 22,007 (22.8%) DNAm
sites and 4,201 (89.0%) expression probes mapping to
3,628 (89.6%) genes—were characterized by a significant
SMR result (significance threshold corrected for the
number of DNAm sites and gene expression probe pairs
tested ¼ p < 1.02 3 107). 6,798 of these significant SMR
pairs—comprising 5,420 (5.61%) DNAm sites and 1,913
(40.5%) expression probes mapping to 1,702 (42.0%)
genes—also had a HEIDI p > 0.05 (Table S8; Figure S15).
These results suggest that although expression of a large
proportion of genes is associated with DNAm sites, not
all DNAm sites are associated with gene expression in cis.ber 1, 2018
FAM173A
CCDC78
HAGHL
NARFL
cg00331210
Transcripts ● ● ●
0.7714 0.7734 0.7754 0.7773 0.7793 0.7813
Chr16:Mb
−log10 SMR P
1
2
3
4
5
6
7
> 7
ACADVL
DVL2
PHF23
GABARAP
CTDNEP1
ELP5
CLDN7
A
B
cg00072720
Transcripts ● ● ●
7.127 7.135 7.143 7.151 7.159 7.167
Chr17:Mb
−log10 SMR P
1
2
3
4
5
6
7
> 7
Figure 4. Regional Plots Demonstrating
the Complex Relationship between Gene
Expression and DNAMethylation as Identi-
fied by SMR
Shown is an example of (A) a DNA-methyl-
ation site (cg00331210) that is associated
with expression of a gene (FAM173A) that
is not the most proximal to it and (B) a
DNA-methylation site (cg00072720) associ-
ated with the expression of multiple genes
(CLDN7 and ELP5). Each plot contains a
gene track, where red arrows indicate the di-
rection of transcription and a red diamond
indicates the position of the pleiotropically
significant DNA-methylation site. Circles
and squares indicate the location of the
gene expression probes that DNA-methyl-
ation sites were tested against. Color indi-
cates the significance level of the SMR test
(black to gray), and green indicates signifi-
cant associations (p < 1.02 3 107). For
significant associations, squares indicate
tests that have non-significant heterogene-
ity (p > 0.05) and are indicative of pleio-
tropic associations.The majority of significant gene expression probes
(n ¼ 1,192; 62.3%) are associated with a median of two
DNAm sites (interquartile range ¼ 1–4) spanning a median
distance of 66,846 bp (interquartile range ¼ 19,062–
155,737) at a median density of 19,959 bp (interquartile
range ¼ 6,387–54,445) between sites. Interestingly, DNAm
sites pleiotropically associated with gene expression are en-
riched in the gene body and transcription start sites of genes
and depleted intergenically (Chi square test p ¼ 7.08 3
10133; Figure S16; Table S9).We identified a small but signif-
icant enrichment of scenarios where DNAm is negatively
associated with gene expression at sites located in the
50 UTR (mean effect ¼ 0.0211; p ¼ 0.00108), TSS200
(mean effect ¼ 0.0479; p ¼ 6.38 3 107), TSS1500 (mean
effect ¼ 0.0350; p ¼ 5.82 3 1011) and 1st exon (mean
effect ¼ 0.0506; p ¼ 6.19 3 105), consistent with the
hypothesis that promoter DNAm often represses gene
expression (Figure S17).
Using QTL Data to Refine the Genic Annotation
Associated with DNAm Sites
A key challenge in epigenetic epidemiology relates to the
genic annotation of DNAm sites; such annotation is critical
for the biological interpretation of significant EWAS associa-
tions. DNAm sites are usually annotated to specific genes on
the basis of proximity, although the extent to which this
approach is valid for inferring downstream transcriptional
effects is not known. Among the identified pleiotropic asso-The American Journal of Human Genciations between DNAm and gene
expression, we selected instanceswhere
the DNAm site is not intergenic—i.e.,
<1500 bp from the transcription start
site of a gene (n ¼ 5,593 [82.3%)]—
and found that these were annotatedto the same gene whose expression level they were associ-
atedwithat amuchhigher rate thanwereDNAmsites signif-
icantly associated with expression levels at another gene
(OR ¼ 9.67; Fisher’s test p < 2.23 3 10308). Of the 5,460
DNAm sites significantly associated with expression of at
least one gene, 1,790 (32.8%) were associated with the
gene they were annotated to, although 276 (5.05%) of
these were also associated to an additional gene and 2,686
(50.0%) were associated with a different gene. Of note, not
all CpGs were tested against the gene they were annotated
to because the gene lacked a significant eQTL; this was the
case for themajority ofDNAmsites (n¼ 2,701; 80.4%) iden-
tifiedasbeingassociatedwitha geneother than theone they
were annotated to.Of particular interest are the 944 (18.3%)
intergenic sites that are associated with gene expression;
these potentially enable additional gene annotations for in-
terpreting the results of EWAS analyses. Overall, although
the proximity-based annotation of DNAm sites appears to
be appropriate in many instances, we identified notable ex-
ceptions. For example, Figure 4A shows that the DNAm site
cg00331210, locatedwithin the body ofNARFL on chromo-
some 16, is not associated with expression of that gene but
with the FAM173A gene, which is located 7.9 kilobases
away. Likewise, Figure 4B shows that the DNAm site
cg00072720, located within the gene body of CLDN7, is
not associated with expression of that gene but with
that of two other genes (ACADVL and ELP5/C17ORF81) on
chromosome 17.etics 103, 654–665, November 1, 2018 661
Discussion
In this study we present a comprehensive assessment of
the genetic architecture of DNAm and identify associations
between common genetic variants and specific DNAm
sites (mQTLs) by using the Illumina EPIC array.We utilized
our database of mQTL associations to characterize genetic
influences on individual and proximally located DNAm
sites. We show that there are many instances of shared
genetic signals on neighboring DNAm sites and that these
associations are structured around both genes and CpG
islands. Our results are in line with the GeMes groups re-
ported by Liu et al., who observed that multiple DNAm
sites were influenced by overlapping genetic variants; their
observations included examples where these DNAm sites
were not contiguous.46 Moreover, we report that these
shared genetic effects on DNAm are generally associated
with positive correlations between the DNAm sites.
This has implications for studies of trait-associated differ-
entially methylated regions (DMRs) because it suggests
that associations with phenotypic variation could be
genetically mediated.
In an extension of our work prioritizing genes in GWAS-
nominated regions,28 we found robust agreement with our
previous SMR findings (obtained from mQTLs identified
with the Illumina 450K array) for shared content by using
independent datasets. The additional content present on
the EPIC array, however, enabled us to identify gene-trait
associations not detected with the older array technology,
increasing the potential yield of biological information.
This augments the existing literature integrating results
from GWASs of complex traits and quantitative trait loci
(QTL) studies of gene expression and DNA methyl-
ation27,57–59 and substantiates the hypothesis that GWAS
variants act via gene regulation. Finally, we use these
data to explore the relationship between DNAm and
gene expression by using genetic instruments rather than
correlations to infer associations between specific DNAm
sites and genes. Although most DNAm sites associated
with gene expression were found to be located within
the gene body or close to the transcription start site, there
are many relationships that challenge the commonly used
genic annotation on the sole basis of physical proximity.
Furthermore, although the expression of most genes is
associated with one or more DNAm sites, not all DNAm
sites are associated with gene expression, implying that
variable DNAm does not always have an effect on gene
expression. These findings are consistent with those re-
ported previously by Bonder et al.60 in their expression
quantitative trait methylation (eQTM) analysis; they also
report the association of multiple DNAm sites with each
gene, the presence of both negative and positive correla-
tions between DNAm and gene expression, and an enrich-
ment of DNAm sites associated with gene expression in the
TSS and enhancers. Although we could only test for associ-
ations between DNAm sites with significant mQTLs and
the expression of genes with a significant eQTL, our results662 The American Journal of Human Genetics 103, 654–665, Novemprovide a potentially effective method for annotating
results from EWAS, particularly where the influence of
DNAm on gene expression is hypothesized and candidates
are taken forward for transcriptional analysis.
Our studyhas anumber of important limitations. The an-
alyses presented here are based on an unrelated subset of
participants from the UKHLS; although these represent a
large sample (>1,000) of European ancestry with a broad
age range, the extent to which our results are applicable
to other ethnic groups characterized by a different genetic
architecture is not known. Despite using the most compre-
hensive, high-throughput technology for profiling DNAm
across the genome (the Illumina EPIC array), our study
only assayed a small proportion of the total number of
DNAm sites and included sparse coverage of regulatory fea-
tures that are often represented by a single DNAm site.40
Moreover, DNAm was profiled in whole blood, which
potentially limits the interpretation of candidate disease
genes where the presumed tissue of interest is not blood.
Given the tissue-specificnature of somemQTLand eQTLef-
fects, these associations should be confirmed in additional
disease-relevant tissues and cell types. AlthoughMendelian
randomization is proposed as a methodology for quanti-
fying causal relationships between variables, it relies on a
number of key assumptions,61 all of which also apply to
SMR. Therefore, our approach did not seek to establish the
direction of association between DNA methylation and
outcome; we are consequently careful in our use of termi-
nology and refrain from describing our associations as
‘‘causal,’’ especially because the SMR approach is unable
to distinguish two causal variants in approximately perfect
LD from one causal variant;27 instead, we refer to these as
‘‘pleiotropic’’ associations. Furthermore, given that our
application of MR is based on a single genetic variant, we
cannot rule out the possibility of horizontal pleiotropy.
Finally, a limitation of the HEIDI approach to distinguish-
ing pleiotropic associations from LD artifacts is that it looks
to accept the null hypothesis of homogeneity of effects
rather than reject it. However, we are confident in the
set of pleiotropic associations we report given the strong
replication of our previous results based on mQTLs esti-
mated in an independent dataset.28
Taken together, our results add to an increasing body
of evidence showing that genetic influences on DNA
methylation are widespread across the genome. We show
that integrating these relationships with the results from
GWAS of complex traits and genetic studies of gene expres-
sion can improve our understanding about the interplay
between gene regulation and expression and facilitate
the prioritization of candidate genes implicated in disease
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